Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230003/S019

Alinity m HR HPV

Abbott Molecular, Inc. · Decision date Sep 2, 2026

FDA DECISIONP230003/S019

What did the FDA decide?

FDA records P230003/S019 as a supplement to PMA P230003, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Sep 2, 2026.

FDA approval order statement

replacement of an instrument part
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Microbiology
Decision date
Sep 2, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P230003/S019
Regulatory pathway
PMA supplement
Product code
MAQ
Decision code
OK30
Decision date
Sep 2, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS.

Product code
MAQ
FDA device class
3

For the original device and its historical approval scope, see PMA P230003. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230003 · Original PMA

    Alinity m HR HPV

  2. P230003/S019 received

    Application receipt date recorded by FDA.

  3. P230003/S019 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P230003. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230003

Product / regulatory recordCompanyPathwayDecision dateSource
Abbott Molecular, Inc.PMA approvalNov 1, 2023FDA

Explore the linked device profile

Other records with product code MAQ

Product / regulatory recordCompanyPathwayDecision dateSource
cobas HPVP100020/S066
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
cobas HPVP190028/S026
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
Roche Molecular Systems, Inc.PMA approvalApr 3, 2020FDA
Roche Molecular Systems, Inc.PMA approvalApr 19, 2011FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Molecular, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1300 E Touhy Ave., Des Plaines, IL, 60018

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records